<DOC>
	<DOCNO>NCT00109161</DOCNO>
	<brief_summary>This research study conduct U.S. Europe evaluate safety efficacy daclizumab treatment multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Study Subcutaneous Daclizumab Patients With Active , Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description>PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Male female age 18 55 year , inclusive . Diagnosis MS McDonald criterion . EDSS &lt; 7.0 . On stable IFNbeta regimen least 6 month . The occurrence either follow within 9 month prior screen : ≥1 MS relapse OR A qualify MRI , define MRI show least one confirm GdCEL brain spinal cord , perform independently study patient stable IFNbeta regimen , deem acceptable central reader . For female , woman nonchildbearing potential woman childbearing potential provide negative serum pregnancy test screen within 24 hour first dose study drug , agree use effective contraception Treatment Followup period study . Willing able comply protocol , provision inform consent accordance institutional regulatory guideline , , US sit , authorization use protect health information . Pregnant breastfeed woman . Nonambulatory patient . Clinically significant abnormality screen ECG . Malignancy within past 5 year , except adequately treat nonmelanoma skin carcinoma situ carcinoma cervix . History HIV infection , positive serology HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) . Varicella ( VZV ) herpes zoster virus infection , severe viral infection , within 6 week screen exposure VZV within 21 day screen . Abnormal hematology , define follow laboratory value : *Hemoglobin ≤8.5 g/dL , *Lymphocytes ≤1.0 x 10^9/L , *Platelets ≤100 x 10^9/L , *Neutrophils ≤1.5 x 10^9/L . Significant organ dysfunction , include limited cardiac , renal , liver , nonMS related CNS , pulmonary , vascular , gastrointestinal , endocrine , metabolic dysfunction , disease condition , opinion PI ( principal investigator ) would make patient unsuitable candidate study . Guidelines level unacceptable dysfunction include : *creatinine ≥1.6 mg/dL ; *AST ALT ≥2.5 time upper limit normal ( ULN ) ; *alkaline phosphatase ≥2.5 time ULN ; *history myocardial infarction , congestive heart failure , arrhythmia within 6 month prior randomization . Use follow : *Any follow type live virus vaccine 4 week randomization : measles/mumps/rubella vaccine , varicella zoster virus vaccine , oral polio vaccine , nasal influenza vaccine . Use vaccine , however , household contact affect eligibility patient enroll continue study ; *Systemic corticosteroid , adrenocorticotropic hormone , plasma exchange within 4 week baseline MRI scan ( 72 hour Day 0 ) ; *Azathioprine , mycophenolate mofetil , methotrexate , glatiramer acetate , intravenous immune globulin within 6 month randomization ; *An immunomodulatory agent within 6 month randomization , except interferonbeta product require per protocol ; *An investigational agent within 6 month randomization unless agent nonimmunomodulatory medical monitor steer committee rule use acceptable theoretical basis lapse least 5 serum halflives since administration last possible dose ; *A monoclonal antibody ( eg , Rituxan®/ Rituximab ) within 6 month randomization ; *Daclizumab time prior randomization ; *Cladribine , mitoxantrone , cyclophosphamide , CamPath® ( alemtuzumab ) , natalizumab ( TYSABRI®/Antegren ) drug target alpha 4 integrin , total lymphoid irradiation , bone marrow transplant time Patients MRI contraindicate , ie , pacemaker contraindicate implanted metal device , allergic gadolinium , claustrophobia medically manage . Primary progressive MS. Clinically unstable 30 day randomization ( Patients experience relapse , without steroid treatment , screen period may rescreened 30 day . ) Elective surgery perform 2 week prior randomization schedule Week 44 Infection ( viral , fungal , bacterial ) require hospitalization IV antibiotic within 8 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Multiple Sclerosis , MS , CNS , Daclizumab</keyword>
</DOC>